Claim OwnershipVJHemOnc Podcast
Subscribed: 56Played: 1,631
Subscribe
© Copyright 2020 All rights reserved.
Description
The Video Journal of Hematology and Hematological Oncology (VJHemOnc) podcast covers the latest hematological oncology and hematology news from international experts - from leukemias, lymphomas, MDS and MPNs, to sickle cell, aplastic anemia and rare diseases.
Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion.
If you enjoy the podcast, please leave us a rating and review!
For more news visit www.vjhemonc.com
Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion.
If you enjoy the podcast, please leave us a rating and review!
For more news visit www.vjhemonc.com
284 Episodes
Reverse
In this podcast episode, leading experts share key updates in the management of myelodysplastic syndromes (MDS) from ASH 2025. Amer Zeidan, MBBS, MHS, Yale School of Medicine, New Haven, CT, highlights data from the MAXILUS trial (NCT06045689), new insights from the IMerge study (NCT02598661), and early findings with bexmarilimab in higher-risk MDS (HR-MDS). This is followed by Valeria Santini, MD, University of Florence, Florence, Italy, who discusses long-term outcomes from IMerge and a post-hoc analysis of the COMMANDS trial (NCT03682536). Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, provides perspective on the Phase III VERONA trial (NCT04401748) of azacitidine plus venetoclax in HR-MDS, and Daniel Wiseman, MBChB, PhD, University of Manchester, Manchester, UK, presents results from the Phase II AMMO study (ISRCTN30808508) in MDS-myeloproliferative neoplasm (MPN) overlap syndromes. Finally, Prof. Santini returns to address current debates and controversial topics in the diagnosis and treatment of MDS.
In this podcast episode, leading experts provide valuable insight into the management of sickle cell disease (SCD). First, Samah Babiker, MBBS, MRCP-UK, FRCPath, Evelina London Children’s Hospital, London, UK, and Payal Desai, MD, Levine Cancer Institute & Wake Forest School of Medicine, Charlotte, NC, discuss the challenges associated with the transition from pediatric to adult care and how to support patients through this period. Following this, Enrico Novelli, MD, MS, University of Pittsburgh, Pittsburgh, PA, shares insight into the management of vaso-occlusive crises, and Subarna Chakravorty, MBBS, FRCPath, MRCPCH, PhD, King’s College Hospital NHS Foundation Trust, London, UK, comments on whether MRI brain assessment should be routinely performed in all patients with SCD.
This episode of the VJHemOnc podcast focuses on accelerated and blast-phase myeloproliferative neoplasms (MPN-AP/BP), offering insights into their diagnosis and management from leading experts.
First, in an interview with Anand Patel, MD, University of Chicago Medical Center, Chicago, IL, you will hear about the diagnosis, risk stratification, and therapeutic strategies being explored for patients with MPN-AP/BP. Dr Patel will also comment on the role and timing of allogeneic stem cell transplantation (alloSCT) in this patient population.
Following this, experts Adam Mead, MA, BM, BCh, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, Charlotte Brierley, MA, BM BCh, MRCP, DPhil, FRCPath, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, and Juan Carlos Hernández-Boluda, MD, PhD, Hospital Clinic of Valencia, Valencia, Spain, will discuss the challenges of managing MPN-AP/BP, highlighting the need for biomarkers to identify patients at risk of aggressive disease progression.
This podcast features experts Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, who debate the value and utility of measurable residual disease (MRD) in the management of adults with newly-diagnosed acute myeloid leukemia (AML). The discussion explores current limitations of MRD assays, the challenges of standardization, and the importance of integrating multiple modalities. This took place at the 7th International Workshop on Acute Leukemias (iwAL 2025), held in Washington, DC.
This episode of the VJHemOnc Podcast features discussions from the 2nd International Workshop on High-Risk Multiple Myeloma (iwHRMM 2025), held in Charleston, SC. First, you will hear from Ross Firestone, MD, PhD, Memorial Sloan Kettering Cancer Center, New York City, NY, Nisha Joseph, MD, Winship Cancer Institute of Emory University, Atlanta, GA, and Ajai Chari, MD, University of California San Francisco, San Francisco, CA, who provide insight into immuno- and targeted therapies in HRMM. This is followed by Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC, and Holly Lee, MD, University of Calgary, Calgary, Canada, who discuss resistance to these therapies, highlighting the mechanisms of resistance and potential strategies to overcome them.
This podcast features discussions from the 22nd International Workshop on Non-Hodgkin Lymphoma (iwNHL), which took place in Cambridge, MA. The discussions focus on immunotherapy and novel combinations being explored for the treatment of NHL. Featuring experts Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, Elizabeth Budde, MD, PhD, City of Hope, Duarte, CA, Lorenzo Falchi, MD, Memorial Sloan Kettering Cancer Center, New York, NY, and Sameh Gaballa, MD, Moffitt Cancer Center, Tampa, FL, who share insights into bispecific antibodies and other immunotherapeutics in early lines of treatment. This is followed by Laurie Sehn, MD, MPH, BC Cancer Agency, Vancouver, Canada, Juan Alderuccio, MD, Sylvester Comprehensive Cancer Center, Miami, FL, and Gilles Salles, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, who delve deeper into antibody-based combinations.
In this episode of the VJHemOnc Podcast, we are joined by Shai Shimony, MD, Dana-Farber Cancer Institute, Boston, MA, and Richard Stone, MD, Dana-Farber Cancer Institute, Boston, MA, to discuss recent guideline updates on the risk stratification and treatment of acute myeloid leukemia (AML). The experts discuss differences in the World Health Organization (WHO) and International Consensus Classification (ICC) definitions, the recent European Leukemia Network (ELN) updates to risk stratification, incorporating measurable residual disease (MRD) into therapeutic decision-making, and biomarkers or stratification approaches on the horizon.
VJHemOnc recently attended the International Workshop on Chronic Lymphocytic Leukemia (XXI iwCLL 2025) in Krakow, Poland, where there was a session focused on the management of CLL in resource-limited settings. Today's podcast episode highlights discussions from this session. First, you will hear from Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, who discusses the development of resource-restricted recommendations for CLL. This is followed by Anna Schuh, MD, PhD, University of Oxford, Oxford, UK, Andrielle Yost, MPA, The Max Foundation, Seattle, WA, and Catherina Scheepers, The Max Foundation, Gauteng, South Africa, who share ongoing projects by iwCLL and The Max Foundation to improve access to treatment and patient outcomes in low- and middle-income countries. Finally, Brian Koffman, MDCM (retired), CLL Society, Inc., Chula Vista, CA, discusses the six principles for excellence that healthcare professionals and patient advocacy organizations should be aware of when caring for patients with CLL.
This episode of our Blood Cancer Awareness Month series explores the role of the multi-disciplinary team in caring for patients with blood cancer undergoing CAR T-cell therapy.
The discussion features insights from Ty Simpson, BN, MNP, Alfred Health, Melbourne, Australia, who is a CAR-T nurse practitioner, and Frederick Vonberg, MD, University College London Hospitals NHS Foundation Trust, London, UK, who is a neurologist with a primary research interest in the neurotoxic effects of CAR T-cell therapy. This is followed by Angela Halley, MBBS, BSc, MSc, FRCP, Royal Marsden Hospital, London, UK, who is a consultant in palliative medicine with an interest in developing early integrated palliative care in hematology, including patients undergoing CAR-T treatment and stem cell transplant.
Welcome to the next episode in our Blood Cancer Awareness Month series. In this podcast, Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA, discusses financial and time toxicities in cancer care, explaining how out-of-pocket costs and the time spent receiving treatment impair patients' lives. Dr Banerjee shares insights from his own clinical experience, with a focus on patients with multiple myeloma.
Welcome to the first episode of our Blood Cancer Awareness Month special on VJHemOnc. In this podcast, leading experts answer your most pressing questions on blood cancers. Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, discusses chronic lymphocytic leukemia (CLL), followed by Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, who addresses key questions on myeloma. Finally, Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, shares insights on lymphoma.
This episode features discussions from the 3rd International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS & iwMPN) 2025, held in Lisbon, Portugal. First, you will hear from Uma Borate, MD, The Ohio State University, Columbus, OH, Luca Lanino, MD, PhD, Yale University, New Haven, CT, Robert Hasserjian, MD, Massachusetts General Hospital, Boston, MA, and Zoey Xie, MD, MS, Moffitt Cancer Center, Tampa, FL, who share updates in the classification and risk stratification of MDS. Hetty Carraway, MD, Cleveland Clinic, Cleveland, OH, and Amy DeZern, MD, MHS, Johns Hopkins University School of Medicine, Baltimore, MD, then go on to discuss novel pathways and therapeutic agents being explored, including telomerase inhibition, the SELECT-MDS-1 study (NCT04797780), and more.
This episode of the VJHemOnc Podcast spotlights advances in the understanding and treatment of Waldenström’s macroglobulinemia (WM), featuring Karan Chohan, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, Anna Maria Frustaci, MD, Niguarda Hospital, Milan, Italy, Neil Berinstein, MD, Sunnybrook Odette Cancer Centre, Toronto, Canada, Chan Cheah, MBBS, FRACP, FRCPA, DMSc, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, and Dima El-Sharkawi, MB, BS, MA, PhD, MRCP, FRCPath, The Royal Marsden NHS Foundation Trust, London, UK.
The experts focus on the impact of MYD88 and TP53 alterations, current treatment approaches including the use of BTK inhibitors (BTKis), and strategies for patients who discontinue BTKis. They then go on to discuss clinical trial advances, including the BRAWM trial (NCT04624906) and BTK degraders.
This podcast focuses on FLT3-ITD-positive acute myeloid leukemia (FLT3-ITD+ AML), featuring experts Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, Musa Yilmaz, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, and Harry Erba, MD, PhD, Duke University, Durham, NC. The episode covers the standard of care for frontline treatment, key trial updates including an analysis of the Quantum-First trial (NCT02668653), and the use of measurable residual disease (MRD) using FLT3-ITD as a marker.
In this episode of the VJHemOnc Podcast, we dive into one of the more aggressive and challenging manifestations of multiple myeloma, extramedullary disease (EMD). We are joined by experts Meral Beksac, MD, Istinye University Ankara Liv Hospital, Ankara, Turkey, Mehmet Samur, PhD, Dana-Farber Cancer Institute, Boston, MA, Saurabh Zanwar, MD, MBBS, Mayo Clinic, Rochester, MN, and Shaji Kumar, MD, Mayo Clinic, Rochester, MN. They discuss the latest insights on how EMD presents, how it’s managed, and what we’re learning about its complex biology. Plus, we’ll explore emerging treatment strategies and clinical trials, including the RedirecTT-1 trial (NCT04586426).
In this week’s VJHemOnc podcast, we’ll be sharing highlights in myeloproliferative neoplasms (MPNs) from the recent 3rd International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS & iwMPN) 2025. First, you will hear a roundtable discussion, in which Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Donal McLornan, MB, BCh, MRCP, PhD, FRCPath, University College London Hospitals, London, UK, and Haifa Kathrin Al-Ali, MD, Krukenberg Cancer Center, Halle, Germany, provide insight into novel approaches for the upfront management of myelofibrosis. The experts discuss the need to define a suboptimal response to therapy and outline some of the agents being investigated for myelofibrosis in the frontline setting.
Following this, Alexander Lyon, MA, BM, BCh, PhD, FRCP, FHFA, Royal Brompton Hospital, London, UK, discusses cardiovascular health in patients with MPNs, and Adrián Mosquera Orgueira, MD, PhD, Santiago Clinic Hospital CHUS, Santiago, Spain, provides insight into the application of artificial intelligence (AI) in the MDS/MPN setting.
In this episode of the VJHemOnc podcast, we are joined by experts Kathryn Tringale, MD, UC San Diego Health, San Diego, CA, and Nikita Dave, MD, University of Pennsylvania, Philadelphia, PA, who share their perspectives on the management of patients with central nervous system (CNS) lymphoma from the 18th International Conference on Malignant Lymphoma (ICML 2025). The discussion covers both primary and secondary CNS lymphoma, providing practical recommendations and guidelines for oncologists, as well as highlighting emerging therapies currently under investigation.
VJHemOnc recently attended the 3rd International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS & iwMPN) 2025, held in Lisbon, Portugal. This episode features experts Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, Elizabeth Griffiths, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, Lisa Pleyer, MD, Paracelsus Medical University, Salzburg, Austria, Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA, and Yasushi Miyazaki, MD, Nagasaki University, Nagasaki, Japan. They begin by summarizing the key themes from their presentations, which cover a wide range of hot topics, including the role of allotransplant in Japan, communicating about drug efficacy in clinical trials, validating response criteria, and optimizing the use of hypomethylating agents. They then have an insightful discussion on how we can enhance clinical trial design and ultimately improve outcomes for patients with MDS.
Today’s episode of the VJHemOnc podcast focuses on the targeting of mutant calreticulin (mutCALR) in myeloproliferative neoplasms (MPNs) – a trending topic in the field! You will hear leading experts Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, discuss what makes mutCALR an attractive therapeutic target in MPNs. Following this, John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, and Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, outline the early results of the clinical trial investigating a mutant CALR-targeted antibody, INCA33989, which were presented as a late breaking abstract at the recent 30th Congress of the European Hematology Association (EHA). Additionally, Prof. Harrison comments on other targeted therapies being evaluated in MPNs. Finally, Alex Rampotas, MBBS, MRCP, University College London, London, UK, and Zoë Wong, BSc, University of Oxford, Oxford, UK, provide insight into the development and evaluation of a novel CAR T-cell therapy targeting mutCALR in myelofibrosis (MF).
This episode of the VJHemOnc podcast focuses on the treatment of elderly or unfit patients with acute myeloid leukemia (AML). Featuring experts Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Gail Roboz, MD, Weill Cornell Medicine, New York City, NY, Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, Joshua Zeidner, MD, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, Nelli Bejanyan, MD, Moffitt Cancer Center, Tampa, FL, Parastoo Dahi, MD, MS, Memorial Sloan Kettering, New York City, NY, and Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania. They discuss the current standard of care in the frontline setting, considerations for transplant eligibility, and future approaches being explored, such as triplet combinations including targeted agents.
Comments
Download from Google Play
Download from App Store
United States